PL184521B1 - Zastosowanie cząsteczki przeciwciała swoistego wobec epitopu kodowanego przez zmienny egzon v genu CD do wytwarzania kompozycji farmaceutycznej do leczenia raka łuskowatokomórkowego - Google Patents
Zastosowanie cząsteczki przeciwciała swoistego wobec epitopu kodowanego przez zmienny egzon v genu CD do wytwarzania kompozycji farmaceutycznej do leczenia raka łuskowatokomórkowegoInfo
- Publication number
- PL184521B1 PL184521B1 PL96327066A PL32706696A PL184521B1 PL 184521 B1 PL184521 B1 PL 184521B1 PL 96327066 A PL96327066 A PL 96327066A PL 32706696 A PL32706696 A PL 32706696A PL 184521 B1 PL184521 B1 PL 184521B1
- Authority
- PL
- Poland
- Prior art keywords
- antibody
- lymph node
- use according
- antibody molecule
- node metastasis
- Prior art date
Links
Classifications
-
- G01N33/575—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19545472A DE19545472A1 (de) | 1995-12-06 | 1995-12-06 | Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen |
| DE19615074 | 1996-04-17 | ||
| PCT/EP1996/005448 WO1997021104A1 (de) | 1995-12-06 | 1996-12-05 | Verfahren zur diagnose und therapie von plattenepithelkarzinomen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL327066A1 PL327066A1 (en) | 1998-11-23 |
| PL184521B1 true PL184521B1 (pl) | 2002-11-29 |
Family
ID=26020988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL96327066A PL184521B1 (pl) | 1995-12-06 | 1996-12-05 | Zastosowanie cząsteczki przeciwciała swoistego wobec epitopu kodowanego przez zmienny egzon v genu CD do wytwarzania kompozycji farmaceutycznej do leczenia raka łuskowatokomórkowego |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP0865609B1 (enExample) |
| JP (1) | JP2000502067A (enExample) |
| KR (1) | KR100473824B1 (enExample) |
| CN (1) | CN1151377C (enExample) |
| AR (1) | AR004360A1 (enExample) |
| AT (1) | ATE235056T1 (enExample) |
| AU (1) | AU726704B2 (enExample) |
| BG (1) | BG62985B1 (enExample) |
| BR (1) | BR9611901A (enExample) |
| CA (1) | CA2239709A1 (enExample) |
| CO (1) | CO4520233A1 (enExample) |
| CZ (1) | CZ174198A3 (enExample) |
| DE (1) | DE59610248D1 (enExample) |
| DK (1) | DK0865609T3 (enExample) |
| EE (1) | EE03783B1 (enExample) |
| ES (1) | ES2190484T3 (enExample) |
| MX (1) | MX9804459A (enExample) |
| NO (1) | NO319903B1 (enExample) |
| NZ (1) | NZ324314A (enExample) |
| PL (1) | PL184521B1 (enExample) |
| PT (1) | PT865609E (enExample) |
| SK (1) | SK284378B6 (enExample) |
| TR (1) | TR199801027T2 (enExample) |
| UY (1) | UY24389A1 (enExample) |
| WO (1) | WO1997021104A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947496B2 (en) * | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7189397B2 (en) * | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US20050100542A1 (en) * | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US20030103985A1 (en) | 2001-05-18 | 2003-06-05 | Boehringer Ingelheim International Gmbh | Cytotoxic CD44 antibody immunoconjugates |
| EP1258255A1 (en) * | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| CN1541226A (zh) * | 2001-05-18 | 2004-10-27 | ���ָ��Ӣ��ķ�������Ϲ�˾ | CD44v6特异性的抗体 |
| US6972324B2 (en) | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
| EP1391213A1 (en) * | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP1417974A1 (en) * | 2002-11-08 | 2004-05-12 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy |
| JP5763105B2 (ja) * | 2010-02-04 | 2015-08-12 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 頭頸部扁平上皮癌の治療に使用されるｃｄ４４に対するモノクローナル抗体 |
| US9218450B2 (en) | 2012-11-29 | 2015-12-22 | Roche Molecular Systems, Inc. | Accurate and fast mapping of reads to genome |
| EP3755717A4 (en) * | 2018-02-22 | 2022-01-26 | Multitude Inc. | THERAPEUTIC ANTIBODY AND USES THEREOF |
| IL317000A (en) | 2022-05-25 | 2025-01-01 | Akiram Therapeutics Ab | Antibodies against CD44V6 and their use in the treatment of cancers that overexpress CD44V6 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69406664T2 (de) * | 1993-06-18 | 1998-06-04 | Biotie Therapies Oy | Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6 |
| WO1995000851A1 (de) * | 1993-06-22 | 1995-01-05 | Boehringer Ingelheim International Gmbh | Verfahren zur diagnose und analyse von tumoren |
| DE4326573A1 (de) * | 1993-08-07 | 1995-02-23 | Boehringer Ingelheim Int | Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren |
| UA58482C2 (uk) * | 1994-06-08 | 2003-08-15 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти |
-
1996
- 1996-12-03 UY UY24389A patent/UY24389A1/es not_active IP Right Cessation
- 1996-12-04 AR ARP960105480A patent/AR004360A1/es unknown
- 1996-12-05 AU AU11773/97A patent/AU726704B2/en not_active Ceased
- 1996-12-05 SK SK736-98A patent/SK284378B6/sk unknown
- 1996-12-05 DE DE59610248T patent/DE59610248D1/de not_active Expired - Fee Related
- 1996-12-05 TR TR1998/01027T patent/TR199801027T2/xx unknown
- 1996-12-05 EE EE9800164A patent/EE03783B1/xx not_active IP Right Cessation
- 1996-12-05 EP EP96942362A patent/EP0865609B1/de not_active Expired - Lifetime
- 1996-12-05 PT PT96942362T patent/PT865609E/pt unknown
- 1996-12-05 CA CA002239709A patent/CA2239709A1/en not_active Abandoned
- 1996-12-05 DK DK96942362T patent/DK0865609T3/da active
- 1996-12-05 CN CNB961992484A patent/CN1151377C/zh not_active Expired - Fee Related
- 1996-12-05 NZ NZ324314A patent/NZ324314A/en unknown
- 1996-12-05 ES ES96942362T patent/ES2190484T3/es not_active Expired - Lifetime
- 1996-12-05 WO PCT/EP1996/005448 patent/WO1997021104A1/de not_active Ceased
- 1996-12-05 JP JP9520993A patent/JP2000502067A/ja not_active Ceased
- 1996-12-05 AT AT96942362T patent/ATE235056T1/de not_active IP Right Cessation
- 1996-12-05 CO CO96063967A patent/CO4520233A1/es unknown
- 1996-12-05 CZ CZ981741A patent/CZ174198A3/cs unknown
- 1996-12-05 PL PL96327066A patent/PL184521B1/pl not_active IP Right Cessation
- 1996-12-05 BR BR9611901A patent/BR9611901A/pt not_active Application Discontinuation
- 1996-12-05 KR KR10-1998-0704242A patent/KR100473824B1/ko not_active Expired - Fee Related
-
1998
- 1998-06-04 MX MX9804459A patent/MX9804459A/es not_active IP Right Cessation
- 1998-06-05 BG BG102513A patent/BG62985B1/bg unknown
- 1998-06-05 NO NO19982588A patent/NO319903B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO319903B1 (no) | 2005-09-26 |
| KR19990071952A (ko) | 1999-09-27 |
| MX9804459A (es) | 1998-09-30 |
| JP2000502067A (ja) | 2000-02-22 |
| EE03783B1 (et) | 2002-06-17 |
| CZ174198A3 (cs) | 1999-02-17 |
| EE9800164A (et) | 1998-12-15 |
| DE59610248D1 (de) | 2003-04-24 |
| UY24389A1 (es) | 2001-10-25 |
| AR004360A1 (es) | 1998-11-04 |
| BR9611901A (pt) | 1999-03-02 |
| CA2239709A1 (en) | 1997-06-12 |
| KR100473824B1 (ko) | 2005-09-30 |
| SK284378B6 (sk) | 2005-02-04 |
| NO982588D0 (no) | 1998-06-05 |
| PL327066A1 (en) | 1998-11-23 |
| ATE235056T1 (de) | 2003-04-15 |
| CN1151377C (zh) | 2004-05-26 |
| NZ324314A (en) | 2000-02-28 |
| HK1011560A1 (en) | 1999-07-16 |
| EP0865609A1 (de) | 1998-09-23 |
| DK0865609T3 (da) | 2003-06-23 |
| AU1177397A (en) | 1997-06-27 |
| BG62985B1 (bg) | 2000-12-29 |
| AU726704B2 (en) | 2000-11-16 |
| PT865609E (pt) | 2003-08-29 |
| NO982588L (no) | 1998-08-05 |
| ES2190484T3 (es) | 2003-08-01 |
| CN1207811A (zh) | 1999-02-10 |
| SK73698A3 (en) | 1999-01-11 |
| BG102513A (en) | 1999-02-26 |
| TR199801027T2 (xx) | 1998-10-21 |
| WO1997021104A1 (de) | 1997-06-12 |
| CO4520233A1 (es) | 1997-10-15 |
| EP0865609B1 (de) | 2003-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5916561A (en) | Monoclonal antibody against CD44v6 | |
| ES2427544T3 (es) | Anticuerpos de RG1 y sus usos | |
| CN101432422A (zh) | 显示trop-2表面表达的细胞的细胞毒性介导 | |
| JP2005538682A (ja) | カルボキシックアンヒドラーゼｉｘ（ｃａｉｘ）腫瘍抗原に対する抗体 | |
| PL184521B1 (pl) | Zastosowanie cząsteczki przeciwciała swoistego wobec epitopu kodowanego przez zmienny egzon v genu CD do wytwarzania kompozycji farmaceutycznej do leczenia raka łuskowatokomórkowego | |
| US6372441B1 (en) | Method for diagnosis and therapy of Hodgkin's lymphomas | |
| CN115109160B (zh) | 抗epcam抗体和双特异性抗体 | |
| CN115109164A (zh) | 靶向epcam和cd3的双特异性抗体 | |
| CA2168988A1 (en) | Polypeptides coded by exon v5 of the cd44 gene as targets for immunotherapy and immunoscintigraphy of tumours | |
| RU2193779C2 (ru) | Средство и способ лечения плоскоклеточного рака | |
| MXPA96006108A (es) | Anticuerpos monoclonales contra cd44v6 | |
| HK1011560B (en) | Method of diagnosing and treating epithelioma | |
| HK1011697B (en) | Monoclonal antibody active against cd44v6 | |
| HK1114124A (en) | Cancer specific antibody and cell surface proteins | |
| MXPA99005544A (es) | Molecula de anticuerpo y su empleo para la diagnosis y terapia de linfomas de hodgkin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20051205 |